Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastrointestinal Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    343 result(s) found for: Gastrointestinal Cancer AND Cancer. Displaying page 13 of 18.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    EudraCT Number: 2006-006538-16 Sponsor Protocol Number: A6181114 Start Date*: 2007-03-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI...
    Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010065-23 Sponsor Protocol Number: P05553 Start Date*: 2009-08-17
    Sponsor Name:Essex Pharma GmbH
    Full Title: Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05...
    Medical condition: Active Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10066678 Acute ulcerative colitis LLT
    14.1 10017947 - Gastrointestinal disorders 10033007 Other ulcerative colitis LLT
    14.1 10017947 - Gastrointestinal disorders 10045366 Ulcerative colitis, unspecified LLT
    14.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000698-22 Sponsor Protocol Number: MK-7339-003 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidine in Participants with ...
    Medical condition: The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) FR (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004373-23 Sponsor Protocol Number: ROV-BEM-2003-02 Start Date*: 2007-08-14
    Sponsor Name:LABORATORIOS FARMACEUTICOS ROVI, S.A.
    Full Title: MULTICENTRIC, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF THE PROPHYLAXIS WITH BEMIPARIN 3,500 IU/day FOR 28 DAYS COMPARED TO 8 DAYS, IN V...
    Medical condition: VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS UNDERGOING ONCOLOGICAL ABDOMINAL OR PELVIC SURGERY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043640 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010921-38 Sponsor Protocol Number: MDL_2009_27155 Start Date*: 2009-09-08
    Sponsor Name:UMC Utrecht
    Full Title: Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot Study
    Medical condition: Ulcerative Colitis and the risk of developing colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001185-32 Sponsor Protocol Number: 38/2007/O/Sper Start Date*: 2007-03-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Protocol for the experimental study about Peritonectomy (CCR) associated with Chemo-Hyperthermic intra-peritonel (CHIP) treatment for primary or secondary peritoneal neoplastic desease (Peritoneal ...
    Medical condition: Peritoneal Carcinosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022991-29 Sponsor Protocol Number: SMR/0211OBD-1033 Start Date*: 2011-02-01
    Sponsor Name:Sucampo Pharma Americas, Inc.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction
    Medical condition: Opioid-induced Bowel Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10061247 Intestinal functional disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002182-21 Sponsor Protocol Number: Vedolizumab-2005 Start Date*: 2017-11-16
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (Long-term Safety With Vedolizumab IV in Pediatric...
    Medical condition: Ulcerative Colitis or Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DE (Prematurely Ended) BE (Completed) NL (Completed) PL (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003342-33 Sponsor Protocol Number: STH16359 Start Date*: 2012-09-28
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Optimising the use of Entonox during screening colonoscopy: an open randomised controlled trial
    Medical condition: Colonoscopy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10010007 Colonoscopy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000927-29 Sponsor Protocol Number: NL60405.100.17 Start Date*: 2017-07-31
    Sponsor Name:Catharina Ziekenhuis
    Full Title: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a mult...
    Medical condition: Isolated unresectable colorectal peritoneal metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002453-11 Sponsor Protocol Number: CFTSp116 Start Date*: 2018-01-19
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-li...
    Medical condition: Poorly differentiated extra-pulmonary neuroendocrine carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004637-16 Sponsor Protocol Number: SLAP Start Date*: 2009-04-28
    Sponsor Name:GISCAD
    Full Title: Folfiri as Second-Line chemotherapy for Advanced Pancreatic cancer: a GISCAD Phase II study
    Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must have been received a first-line chemotherapy (one line only) w...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10013250 Disorder pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001515-23 Sponsor Protocol Number: PROICM2019-03MES Start Date*: 2020-01-29
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma
    Medical condition: Patient with Histologically-confirmed diagnosis of peritoneal malignant mesothelioma and non eligible for cytoreductive surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000560-37 Sponsor Protocol Number: IOV-CAR-01-2020PIPAC Start Date*: 2020-11-30
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO - IRCCS
    Full Title: Pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal carcinomatosis. PIPAC-IOV study. Single-center, single-arm open-label phase II clinical trial
    Medical condition: Peritoneal carcinomatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068069 Peritoneal carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004730-28 Sponsor Protocol Number: FFCD1701 Start Date*: 2019-09-17
    Sponsor Name:fédération francophone de cancérologie digestive
    Full Title: Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Medical condition: METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053548 Gastrointestinal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001518-25 Sponsor Protocol Number: P-Monofer-IDA-02 Start Date*: 2014-11-21
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) against Placebo in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unrespon...
    Medical condition: Subjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anae...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000171-13 Sponsor Protocol Number: P23 Start Date*: 2023-08-23
    Sponsor Name:leiden university medical center
    Full Title: SGM-101 tumor-targeted fluorescence endoscopy to enable discrimination of malignant from benign tissue in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia: a feasibility study
    Medical condition: Early rectal cancer/ big polyps with suspected T1 rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10017947 - Gastrointestinal disorders 10038074 Rectal polyp PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000878-11 Sponsor Protocol Number: OMO1.01.02 Start Date*: 2017-06-08
    Sponsor Name:OCTIMET Oncology NV
    Full Title: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanc...
    Medical condition: Locally advanced, unresectable or metastatic solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 09:23:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA